Personalized medicine in lung cancer: what we need to know

被引：122

作者：

Mok, Tony S. K. ^{[1
]}

机构：

[1] Chinese Univ Hong Kong, State Key Lab S China, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2011年 / 8卷 / 11期

关键词：

FACTOR RECEPTOR MUTATIONS; PREVIOUSLY TREATED PATIENTS; PHASE-II TRIAL; GENE-MUTATIONS; ACQUIRED-RESISTANCE; RANDOMIZED-TRIAL; SUPPORTIVE CARE; KRAS MUTATIONS; EGFR MUTATIONS; GEFITINIB;

D O I：

10.1038/nrclinonc.2011.126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for personalized medicine for lung cancer. Patients selected using biomarkers have benefited from the development of EGFR tyrosine kinase inhibitors and ALK inhibitors with considerable improvement in tumor control and survival. Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance.

引用

页码：661 / 668

页数：8

共 59 条

[1] [Anonymous], J CLIN ONCOL
[2] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Atkinson, AJ
Colburn, WA
DeGruttola, VG
DeMets, DL
Downing, GJ
Hoth, DF
Oates, JA
Peck, CC
Schooley, RT
Spilker, BA
Woodcock, J
Zeger, SL
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
[3] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
Azzoli, Christopher G.
Baker, Sherman, Jr.
Temin, Sarah
Pao, William
Aliff, Timothy
Brahmer, Julie
Johnson, David H.
Laskin, Janessa L.
Masters, Gregory
Milton, Daniel
Nordquist, Luke
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Reily
Smith, Thomas J.
Strawn, John R.
Trent, David
Giaccone, Giuseppe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6251 - 6266
[4] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Bean, James
Brennan, Cameron
Shih, Jin-Yuan
Riely, Gregory
Viale, Agnes
Wang, Lu
Chitale, Dhananjay
Motoi, Noriko
Szoke, Janos
Broderick, Stephen
Balak, Marissa
Chang, Wen-Cheng
Yu, Chong-Jen
Gazdar, Adi
Pass, Harvey
Rusch, Valerie
Gerald, William
Huang, Shiu-Feng
Yang, Pan-Chyr
Miller, Vincent
Ladany, Marc
Yang, Chih-Hsin
Pao, William
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) : 20932 - 20937
[5] The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors
Belani, Chandra P.
[J]. CANCER INVESTIGATION, 2010, 28 (04) : 413 - 423
[6] Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
Burdett, S.
Stephens, R.
Stewart, L.
Tierney, J.
Auperin, A.
Le Chevalier, T.
Le Pechoux, C.
Pignon, J. P.
Arriagada, R.
Higgins, J.
Johnson, D.
van Meerbeeck, J.
Parmar, M.
Souhami, R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4617 - 4625
[7] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Young Lim
Soda, Manabu
Yamashita, Yoshihiro
Ueno, Toshihide
Takashima, Junpei
Nakajima, Takahiro
Yatabe, Yasushi
Takeuchi, Kengo
Hamada, Toru
Haruta, Hidenori
Ishikawa, Yuichi
Kimura, Hideki
Mitsudomi, Tetsuya
Tanio, Yoshiro
Mano, Hiroyuki
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1734 - 1739
[8] Somatic mutations affect key pathways in lung adenocarcinoma
Ding, Li
Getz, Gad
Wheeler, David A.
Mardis, Elaine R.
McLellan, Michael D.
Cibulskis, Kristian
Sougnez, Carrie
Greulich, Heidi
Muzny, Donna M.
Morgan, Margaret B.
Fulton, Lucinda
Fulton, Robert S.
Zhang, Qunyuan
Wendl, Michael C.
Lawrence, Michael S.
Larson, David E.
Chen, Ken
Dooling, David J.
Sabo, Aniko
Hawes, Alicia C.
Shen, Hua
Jhangiani, Shalini N.
Lewis, Lora R.
Hall, Otis
Zhu, Yiming
Mathew, Tittu
Ren, Yanru
Yao, Jiqiang
Scherer, Steven E.
Clerc, Kerstin
Metcalf, Ginger A.
Ng, Brian
Milosavljevic, Aleksandar
Gonzalez-Garay, Manuel L.
Osborne, John R.
Meyer, Rick
Shi, Xiaoqi
Tang, Yuzhu
Koboldt, Daniel C.
Lin, Ling
Abbott, Rachel
Miner, Tracie L.
Pohl, Craig
Fewell, Ginger
Haipek, Carrie
Schmidt, Heather
Dunford-Shore, Brian H.
Kraja, Aldi
Crosby, Seth D.
Sawyer, Christopher S.
[J]. NATURE, 2008, 455 (7216) : 1069 - 1075
[9] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Engelman, Jeffrey A.
Zejnullahu, Kreshnik
Mitsudomi, Tetsuya
Song, Youngchul
Hyland, Courtney
Park, Joon Oh
Lindeman, Neal
Gale, Christopher-Michael
Zhao, Xiaojun
Christensen, James
Kosaka, Takayuki
Holmes, Alison J.
Rogers, Andrew M.
Cappuzzo, Federico
Mok, Tony
Lee, Charles
Johnson, Bruce E.
Cantley, Lewis C.
Janne, Pasi A.
[J]. SCIENCE, 2007, 316 (5827) : 1039 - 1043
[10] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
Fukuoka, M
Yano, S
Giaccone, G
Tamura, T
Nakagawa, K
Douillard, JY
Nishiwaki, Y
Vansteenkiste, J
Kudoh, S
Rischin, D
Eek, R
Horai, T
Noda, K
Takata, I
Smit, E
Averbuch, S
Macleod, A
Feyereislova, A
Dong, RP
Baselga, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246

← 1 2 3 4 5 6 →